目的 分析2014—2016年遼寧省腫瘤醫(yī)院抗生素類抗腫瘤藥物的使用情況，為臨床合理應(yīng)用抗腫瘤藥物提供參考。方法 對(duì)2014—2016年遼寧省腫瘤醫(yī)院抗生素類抗腫瘤藥物的使用金額、用藥頻度（DDDs）、日均費(fèi)用（DDC）及藥品排序比（B/A）進(jìn)行統(tǒng)計(jì)與分析。結(jié)果 2014—2016年抗生素類抗腫瘤藥物的總使用金額和DDDs未出現(xiàn)逐年增長(zhǎng)的趨勢(shì)。吡柔比星的使用金額逐年遞增。表柔比星、多柔比星脂質(zhì)體、多柔比星使用金額逐年遞減。從排序來(lái)看，表柔比星、吡柔比星與多柔比星脂質(zhì)體的使用金額連續(xù)3年排前3位。表柔比星與吡柔比星的DDDs排名持續(xù)居于前2位?？股仡惪鼓[瘤藥物的DDC及其排序相對(duì)穩(wěn)定，多柔比星脂質(zhì)體的DDC持續(xù)居于首位。大部分抗生素類抗腫瘤藥物的B/A值接近于1.00。結(jié)論 遼寧省腫瘤醫(yī)院抗生素類抗腫瘤藥物使用基本合理，符合安全、有效、經(jīng)濟(jì)、方便的原則。

Objective To analyze the usage of antitumor antibiotics in Liaoning Cancer Hospital and Institute, and to provide reference for rational use of antitumor antibiotics. Methods The utilization information of antitumor antibiotics in Liaoning Cancer Hospital and Institute from 2014 to 2016 was extracted, and the consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2014 to 2016, the total consumption sums and DDDs of antitumor antibiotics were not increasing year by year. The consumption sums of pirarubicin increased year by year, while the consumption sums of epirubicin, liposomal doxorubicin, and doxorubicin decreased. From the terms of sequences, epirubicin, liposomal doxorubicin, and pirarubicin ranked the top 3 for three years. DDDs of epirubicin and pirarubicin ranked the top 2. DDC and sequences of antitumor antibiotics were relatively stable. B/A of most antitumor antibiotics were close to 1.00.Conclusion The utilization of antitumor antibiotics in Liaoning Cancer Hospital and Institute is reasonable on the whole, according with the principle of safety, effectiveness, economy, and convenience.